Acute idiopathic pancreatitis is associated with more aggressive disease course in Crohn’s disease but not in ulcerative colitis

Table 1 Baseline characteristics of cohort

Variables	Crohn’s Disease (n = 29)	Ulcerative colitis (n = 24)	P-value
Duration of IBD (y)	24.51 (5.23–30.94)	15.31 (5.12–29.54)	0.64
Age (y)	51.04 (39.58–69.44)	52.02 (34.32–74.75)	0.94
Duration of hospitalization (d)	3.00 (2.00–4.00)	3.00 (2.00-4.75)	0.67
Female	17 (58.62%)	14 (58.33%)	0.98
Smoking	18 (62.07%)	11 (45.83%)	0.24
Biologics	8 (27.59%)	4 (16.67%)	0.34
Extra-intestinal manifestations ¶	13 (44.83%)	6 (25.00%)	0.13
Pancreatitis			0.47
Idiopathic pancreatitis	11 (37.93%)	9 (37.50%)
Cholelithiasis	6 (20.69%) †	3 (12.50%)
Alcoholic	3 (10.34%)	3 (12.50%)
Medication ‡	2 (6.90%)	3 (12.50%)
Hypertriglyceridemia	1 (3.45%)	1 (4.17%)
ERCP	2 (6.90%)	4 (16.67%)
Autoimmune	0	1 (4.17%)
Malignancy	4 (13.79%)	0
Recurrence of pancreatitis	7 (24.14%)	7 (29.17%)	0.68

Abbreviations: AP, Acute Pancreatitis; y, years; d, days; ERCP, Endoscopic Retrograde Cholangiopancreatography
¶ In the Crohn’s disease group, the extra-intestinal manifestations were peripheral arthritis (n = 6), axial arthritis (n = 2), both peripheral and axial arthritis (n = 1), erythema nodosum (n = 1), pyoderma gangrenosum (n = 1), and primary sclerosing cholangitis (n = 2). In the ulcerative colitis group, the extra-intestinal manifestations were peripheral arthritis (n=), and primary sclerosing cholangitis (n = 5)
† One patient in the Crohn’s Disease cohort had an episode of gallstone-induced pancreatitis and then had a subsequent episode of ERCP-induced pancreatitis
‡ Both patients who had medication-induced pancreatitis in the Crohn’s Disease cohort were due to mercaptopurine. Medication-induced pancreatitis in the Ulcerative Colitis cohort were attributed to Azathioprine, Mercaptopurine and Trimethoprim/Sulfamethoxazole.

ISSN: 1471-230X